fast: a phase iii trial of an anti-cldn18.2 antibody gej adenocarcinoma
Published 8 years ago • 544 plays • Length 8:41Download video MP4
Download video MP3
Similar videos
-
1:35
assessing the prevalence of cldn18.2 in gastric/gastroesophageal cancers
-
2:49
spotlight: zolbetuximab and m-folfox6 in cldn18.2 , her2- gej cancer
-
0:51
claudin 18.2 as an emerging target in gastrointestinal cancers
-
2:16
safety and efficacy of a cldn18.2-specific car t-cell therapy in gi adenocarcinoma
-
2:08
targeting cldn18.2 with zolbetuximab in gastric and gej cancer
-
0:34
expanding indications for a cldn18.2-specific car t-cell therapy in gi cancers
-
2:17
claudin 18.2 and fgfr2b as novel targets in gastric cancer
-
0:58
lb1908: a novel car-t cell therapy targeting claudin 18.2 in gi malignancies
-
1:44
what role will zolbetuximab play in treating gastric cancer?
-
1:07
claudin 18.2: a biomarker for gastric cancer
-
1:33
transtar101: osemitamab, a novel cldn18.2 inhibitor, in solid tumors
-
3:03
targeted therapies for gastroesophageal adenocarcinoma
-
7:21
neo-aegis: preliminary results of the phase iii rct of cross versus perioperative chemotherapy
-
1:45
the rationale behind the mif-targeting antibody on203 for solid tumors
-
3:23
antibody-drug conjugates in the treatment of solid tumors
-
3:18
immune checkpoint inhibitors and combination strategies for patients with gastric cancer
-
4:06
bemarituzumab in solid tumors
-
1:42
fast forward phase iii: hypofractionated whole breast irradiation
-
1:04
dr. ilson on the utility of zolbetuximab in claudin-positive gastric cancers